Johnson & Johnson
will seek to have a legal defeat reversed in its ongoing patent litigation with
over drug-coated cardiac stents.
A Delaware jury ruled Friday that J&J breached patents covering the artery-repairing devices in four stents manufactured by its Cordis unit. The ruling sent shares of Boston Scientific up 9% to $29.41 in premarket trading Monday morning.
J&J said it will seek to have the ruling overturned.
A jury in the same court found two weeks ago that four Boston Scientific stents infringed on J&J patents. Wall Street expects Friday's ruling to strengthen Boston Scientific's position in potential licensing negotiations between the two companies.
Boston Scientific said in a statement that the ruling "confirms our belief that we have fundamental intellectual property covering drug-eluting stent technology and stent design."
Shares of Johnson & Johnson were unchanged Tuesday at $64.95.